Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Moodys
Queensland Health
UBS
Dow
QuintilesIMS
McKesson
Julphar
Merck
Mallinckrodt

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,377,474

« Back to Dashboard

Which drugs does patent 8,377,474 protect, and when does it expire?

Patent 8,377,474 protects RYTARY and is included in one NDA.

This patent has twenty-two patent family members in eleven countries.
Summary for Patent: 8,377,474
Title:Controlled release formulations of levodopa and uses thereof
Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
Inventor(s): Hsu; Ann (Los Altos Hills, CA), Kou; Jim H. (San Jose, CA), Alani; Laman (Hillsborough, CA)
Assignee: Impax Laboratories, Inc. (Hayward, CA)
Application Number:12/599,668
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use; Dosage form;

Drugs Protected by US Patent 8,377,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-001 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-001 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-002 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-002 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-003 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-003 Jan 7, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-004 Jan 7, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION ➤ Subscribe
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-004 Jan 7, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,377,474

PCT Information
PCT FiledDecember 26, 2008PCT Application Number:PCT/US2008/014080
PCT Publication Date:July 09, 2009PCT Publication Number: WO2009/085306

Non-Orange Book US Patents Family Members for Patent 8,377,474

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,463,246 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
8,454,998 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
8,557,283 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
9,533,046 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
9,089,608 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
9,089,607 Controlled release formulations of levodopa and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,377,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2011507956 ➤ Subscribe
Japan 5783725 ➤ Subscribe
Israel 206756 ➤ Subscribe
Japan 2015187178 ➤ Subscribe
Japan 6033373 ➤ Subscribe
Israel 248520 ➤ Subscribe
Japan 2017014295 ➤ Subscribe
South Korea 20100099731 ➤ Subscribe
South Korea 101451564 ➤ Subscribe
South Korea 20130113533 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Moodys
Teva
Daiichi Sankyo
Express Scripts
Cantor Fitzgerald
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot